Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.54 |
| ▸ | MTTP | P55157 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.43 |
| ▸ | APOB | P04114 | 5/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793896 | 0.91 | SMO (0.54) | SMOMTTPKDM4ENR3C1APOB | |
| SCHEMBL6795015 | 0.82 | SMO (0.57) | SMOMTTPKDM4ENR3C1APOB | |
| SCHEMBL6799155 | 0.81 | SMO (0.57) | SMOMTTPAPOBTRPV1 | |
| SCHEMBL6795353 | 0.81 | SMO (0.60) | SMOMTTPKDM4EALDH1A1LMNA | |
| SCHEMBL6790830 | 0.81 | SMO (0.56) | SMOMTTPKDM4EAPOBTRPV1 | |
| SCHEMBL6792796 | 0.80 | SMO (0.59) | SMOMTTPALDH1A1LMNANR3C1 | |
| SCHEMBL6795032 | 0.79 | SMO (0.54) | SMOMTTPNR3C1APOBTRPV1 | |
| SCHEMBL6799363 | 0.78 | SMO (0.56) | SMOMTTPNR3C1APOBTRPV1 | |
| SCHEMBL6800605 | 0.78 | SMO (0.53) | SMOMTTPAPOBTRPV1 | |
| SCHEMBL6794354 | 0.77 | SMO (0.61) | SMOMTTPLMNANR3C1APOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | SMO 2094/4885MTTP 363/4885KDM4E 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.